A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer

BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is dysregulated in small-cell lung cancer (SCLC) and everolimus is an oral mTOR inhibitor. METHODS: This phase-1b study assessed everolimus safety at the levels of 2.5, 5, or 10 mg once daily in combination with paclitaxel (175 mg m(−2)) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, J M, Kim, J R, Do, I G, Lee, S Y, Lee, J, Choi, Y L, Ahn, J S, Ahn, M J, Park, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776982/
https://www.ncbi.nlm.nih.gov/pubmed/23963141
http://dx.doi.org/10.1038/bjc.2013.467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776982/
https://www.ncbi.nlm.nih.gov/pubmed/23963141
http://dx.doi.org/10.1038/bjc.2013.467

Ejemplares similares